Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-MEGACHOP Stratification in Poor Prognosis DLBCL
NCT01361191Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Jun 2007
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide, pegylated liposomal doxorubicin, vincristine sulfate liposome injection and prednisone in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by GELTAMO. Primary endpoint: Event Free Survival at 3 years. Started Jun 2007; status: completed.
02
Drugs
rituximabcyclophosphamidepegylated liposomal doxorubicinvincristine sulfate liposome injectionprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01361191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01361191.